How Successful Investors Get RICH

Learn everything you need to know in 'The Canadian Guide on How to Invest in Stocks Successfully' for FREE from The Successful Investor.

How to Invest In Stocks Guide: Find 10 factors that make your investments safer and stronger.

 I consent to receiving information from The Successful Investor via email. I understand I can unsubscribe from these updates at any time.

Topic: How To Invest

$1.1 billion in takeovers spur growth for Bard

Stock Investing

Every Thursday we bring you one of our best U.S. stock picks. You get our specific recommendation on the stocks we profile, with a full explanation of how we arrived at our opinion. You will read about stocks making moves you should know about, most often from coverage in our newsletter on U.S. investing, Wall Street Stock Forecaster.

C.R. BARD INC. (New York symbol BCR; www.crbard.com) makes over 15,000 medical devices in four main areas: oncology products that detect and treat various types of cancer (28% of 2013 sales); vascular products, like stents and catheters (27%); urology goods, such as drainage and incontinence devices (26%); and surgical tools (16%). Other medical products supply the remaining 3%.

The company’s products are typically only used once, so customers must continually buy new ones.

Bard is also benefiting from its new growth strategy, which involves selling slower-growing businesses and buying other medical device makers.

In the past three years, Bard has spent over $1.1 billion on acquisitions. That includes $298.0 million for Lutonix, which has developed a drug-coated balloon for treating clogged leg arteries. Regulators recently approved this product for sale in the U.S.

Bard also paid $262.3 million for Rochester Medical, which makes disposable medical catheters and incontinence products for patients with urinary and bladder conditions.

Thanks to acquisitions, Bard’s sales rose 20.3%, from $2.5 billion in 2009 to $3.05 billion in 2013. Earnings gained 11.7%, from $509.5 million in 2009 to $568.9 million in 2011. Due to fewer shares outstanding, earnings per share jumped 25.7%, from $5.09 to $6.40. However, earnings fell to $6.57 a share (or a total of $565.3 million) in 2012 and to $5.78 a share (or $474.9 million) in 2013.


“Greatest performance consistency”

The most successful Canadian investors have as much as 25% of their portfolios in U.S. stocks. Pat McKeough will help you build the same profit potential and diversification into your portfolio with his proven record of picking the best U.S. stocks.

Pat’s special advisory on U.S. investing has the endorsement of Hulbert Financial Digest, the independent authority on investment newsletter performance. In its latest edition, Hulbert ranks Wall Street Stock Forecaster among “newsletters with the greatest performance consistency over the past decade” with an annual average return of 10.6%. Wall Street is one of only seven newsletters on this list. And the only Canadian one.

Pat will reveal his U.S. Stock of the Year on January 30, 2015. You can be among the first to see it with a no-risk introductory subscription. And you can start profiting immediately from our weekly Hotline updates and recommendations.

Click here to get started now.


Investing in stocks: Republican Congress could hoist Bard’s profits with excise tax repeal

The main reason for the earnings drop was that Bard boosted its research spending by 45.5%, from $203.2 million (or 6.9% of sales) in 2012 to $295.7 million (or 9.7%) in 2013.

Another part of Bard’s strategy involves expanding sales outside of the U.S., which accounts for two-thirds of its total sales. The company believes its sales to clients in emerging markets like China, India, Russia and Turkey could more than double by 2020.

Bard’s balance sheet remains sound. Even after its recent acquisitions, its goodwill was $1.1 billion as of September 30, 2014, or a low 9% of its market cap. Its long-term debt was a moderate $1.4 billion, and it held cash of $971.7 million, or $12.97 a share.

However, Bard’s profits could rise more quickly in the next few years. That’s because the Republicans now control the U.S. Congress, and they have pledged to repeal the 2.3% excise tax on medical device makers under Obamacare. The stock’s $0.88-a-share annual dividend yields 0.5%.

C.R. Bard is a buy recommendation of our advisory on U.S. investing, Wall Street Stock Forecaster.

Comments

Tell Us What YOU Think

You must be logged in to post a comment.

Please be respectful with your comments and help us keep this an area that everyone can enjoy. If you believe a comment is abusive or otherwise violates our Terms of Use, please click here to report it to the administrator.